"Research use only" is a confession, not a disclaimer

When the price is that far below everyone else’s, it is not a sourcing advantage. It is the sound of every safeguard being removed.

What is missing

An overseas grey-market seller offers no US license, no inspections, no required prescription, no certificate of analysis, and no recourse if the product harms you or simply never arrives.

The consequences follow directly. You cannot verify the active ingredient, so it may be counterfeit or a different compound entirely. You cannot verify the dose, so it may be a fraction of what is claimed or a dangerous multiple of it. You cannot verify the chemical form. The FDA has specifically warned that some products use salt forms such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the base form in approved medicines and have not been shown to be safe or effective. And because it is an injectable manufactured outside any sterile standard, it can carry bacterial contamination, endotoxins, heavy metals or other impurities.

There is a legal dimension too. Importing unapproved prescription drugs into the US generally violates federal law. The FDA can refuse or seize these shipments and has documented counterfeit product in the US supply chain. A seized package means the money is gone with no recourse. So does a seller who takes payment and disappears, which is common.

The labelling dodge

Compounds like BPC-157, TB-500, tesamorelin and GHK-Cu are overwhelmingly sold overseas as “research chemicals,” and most are not FDA-approved for the uses they are marketed for.

The “research use only” and “not for human consumption” labelling is worth naming precisely. It is a legal manoeuvre to avoid the rules governing medicines, while everyone involved understands the buyer intends to inject the product. It is not a disclaimer that can be waved past. It is an admission that nothing about the product was made, tested or handled to a medical standard, and that the buyer is assuming all of the risk. The framing is the entire business model, precisely because it removes every obligation the seller would otherwise carry.

What a licensed pharmacy does instead

A US-based, state-licensed compounding pharmacy prepares medication against a prescription written by an independent, licensed provider. It tests batches for potency, purity and sterility. It provides a certificate of analysis on request. It operates at a verifiable address under state pharmacy board oversight: a real business that can be identified and held accountable.

Compounded medication is still not FDA-approved, and that should be said plainly rather than buried. But it arrives with a stack of real, verifiable controls that no overseas source offers at any price. That is the actual comparison: not approved versus unapproved, but controlled versus uncontrolled.

The question we owe ourselves

It would be easy to stop there, having drawn a flattering comparison. So here is the same question turned on us.

Where Amerigo Health or the brands it operates are involved in compounded medication, that medication is prepared by US-based, state-licensed pharmacies. That is the claim, and it is the whole claim.

What we cannot tell you is where those pharmacies source their active pharmaceutical ingredient. API supply chains are global, including for FDA-approved medicines sitting in American pharmacies today, and a compounding pharmacy’s own sourcing is not something a customer, or we, can independently verify. We do not control it, and we are not going to claim we do.

That is a narrower statement than “we do not source from overseas,” which is what an earlier version of this note said. The narrower one is the true one. An article arguing that opacity about sourcing should disqualify a seller does not get to be vague about its own.

Where the evidence is thin

We would flag one thing about how this argument is usually made, including here. The failure modes above are structural and well-reasoned, but they are stated generally. We are not aware of a published assay series testing grey-market GLP-1 samples at scale and reporting what fraction were underdosed, contaminated or misidentified.

That study would be worth having. Its absence does not make the argument wrong: the absence of controls is the point, and does not require an incident count to be true. But an evidence page should be honest about which of its claims rest on data and which rest on reasoning. This one rests on reasoning.